Loading...

Pharmagest Interactive

ENXTPA:PHA
Snowflake Description

Excellent balance sheet with solid track record and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PHA
ENXTPA
€919M
Market Cap
  1. Home
  2. FR
  3. Healthcare
Company description

Pharmagest Interactive SA engages in the development and commercialization of IT solutions for pharmacies and the pharmaceutical industry in Europe. The last earnings update was 148 days ago. More info.


Add to Portfolio Compare Print Invest
PHA Share Price and Events
Price Volatility
PHA
Industry
5yr Volatility vs Market
Related Companies

PHA Value

 Is Pharmagest Interactive undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Pharmagest Interactive to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Pharmagest Interactive.

ENXTPA:PHA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.8%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:PHA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.8%
Equity Risk Premium S&P Global 9.2%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.56
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.559 (1 + (1- 33%) (1.84%))
0.565
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.78% + (0.8 * 9.22%)
8.16%

Discounted Cash Flow Calculation for ENXTPA:PHA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Pharmagest Interactive is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:PHA DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 29.20 38.05 40.00 42.04 44.19
Source Analyst x2 Analyst x2 Est @ 5.11% Est @ 5.11% Est @ 5.11%
Present Value
Discounted (@ 8.16%)
27.00 32.53 31.61 30.72 29.86
Present value of next 5 years cash flows €151.72
ENXTPA:PHA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €44.19 × (1 + 0.78%) ÷ (8.16% – 0.78%)
€603.64
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €603.64 ÷ (1 + 8.16%)5
€407.88
ENXTPA:PHA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €151.72 + €407.88
€559.61
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €559.61 / 14.95
€37.43
ENXTPA:PHA Discount to Share Price
Calculation Result
Value per share (EUR) From above. €37.43
Current discount Discount to share price of €61.50
= -1 x (€61.50 - €37.43) / €37.43
-64.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Pharmagest Interactive is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pharmagest Interactive's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pharmagest Interactive's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:PHA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2017-12-31) in EUR €1.55
ENXTPA:PHA Share Price ** ENXTPA (2018-09-21) in EUR €61.5
Europe Healthcare Services Industry PE Ratio Median Figure of 19 Publicly-Listed Healthcare Services Companies 32.33x
France Market PE Ratio Median Figure of 396 Publicly-Listed Companies 17.04x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pharmagest Interactive.

ENXTPA:PHA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:PHA Share Price ÷ EPS (both in EUR)

= 61.5 ÷ 1.55

39.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmagest Interactive is overvalued based on earnings compared to the Europe Healthcare Services industry average.
  • Pharmagest Interactive is overvalued based on earnings compared to the France market.
Price based on expected Growth
Does Pharmagest Interactive's expected growth come at a high price?
Raw Data
ENXTPA:PHA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 39.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
15.5%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.28x
France Market PEG Ratio Median Figure of 257 Publicly-Listed Companies 1.7x

*Line of best fit is calculated by linear regression .

ENXTPA:PHA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 39.74x ÷ 15.5%

2.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmagest Interactive is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Pharmagest Interactive's assets?
Raw Data
ENXTPA:PHA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2017-12-31) in EUR €7.58
ENXTPA:PHA Share Price * ENXTPA (2018-09-21) in EUR €61.5
France Healthcare Services Industry PB Ratio Median Figure of 8 Publicly-Listed Healthcare Services Companies 2.33x
France Market PB Ratio Median Figure of 589 Publicly-Listed Companies 1.67x
ENXTPA:PHA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:PHA Share Price ÷ Book Value per Share (both in EUR)

= 61.5 ÷ 7.58

8.12x

* Primary Listing of Pharmagest Interactive.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pharmagest Interactive is overvalued based on assets compared to the FR Healthcare Services industry average.
X
Value checks
We assess Pharmagest Interactive's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Pharmagest Interactive has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PHA Future Performance

 How is Pharmagest Interactive expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pharmagest Interactive expected to grow at an attractive rate?
  • Pharmagest Interactive's earnings growth is expected to exceed the low risk savings rate of 0.8%.
Growth vs Market Checks
  • Pharmagest Interactive's earnings growth is expected to exceed the France market average.
  • Pharmagest Interactive's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:PHA Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:PHA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 15.5%
ENXTPA:PHA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 10.1%
France Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 25.9%
France Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 11.1%
France Market Earnings Growth Rate Market Cap Weighted Average 10.8%
France Market Revenue Growth Rate Market Cap Weighted Average 4.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:PHA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:PHA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 243 1
2021-12-31 217 1
2020-12-31 177 45 37 3
2019-12-31 162 38 31 3
2018-12-31 147 34 27 2
ENXTPA:PHA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2017-12-31 147 27 23
2017-09-30 142 26 22
2017-06-30 137 25 21
2017-03-31 133 24 21
2016-12-31 128 23 21
2016-09-30 125 22 20
2016-06-30 121 22 20
2016-03-31 117 21 19
2015-12-31 113 20 19
2015-09-30 113 20 18
2015-06-30 112 21 18
2015-03-31 113 19 17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pharmagest Interactive's earnings are expected to grow by 15.5% yearly, however this is not considered high growth (20% yearly).
  • Pharmagest Interactive's revenue is expected to grow by 10.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:PHA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Pharmagest Interactive Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:PHA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 2.37 2.55 2.12 3.00
2019-12-31 2.01 2.18 1.81 3.00
2018-12-31 1.71 1.78 1.65 2.00
ENXTPA:PHA Past Financials Data
Date (Data in EUR Millions) EPS *
2017-12-31 1.55
2017-09-30 1.48
2017-06-30 1.41
2017-03-31 1.39
2016-12-31 1.37
2016-09-30 1.34
2016-06-30 1.31
2016-03-31 1.28
2015-12-31 1.25
2015-09-30 1.22
2015-06-30 1.18
2015-03-31 1.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Pharmagest Interactive is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Pharmagest Interactive's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pharmagest Interactive has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PHA Past Performance

  How has Pharmagest Interactive performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pharmagest Interactive's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pharmagest Interactive's year on year earnings growth rate has been positive over the past 5 years.
  • Pharmagest Interactive's 1-year earnings growth exceeds its 5-year average (12.5% vs 9.6%)
  • Pharmagest Interactive's earnings growth has exceeded the Europe Healthcare Services industry average in the past year (12.5% vs 4.9%).
Earnings and Revenue History
Pharmagest Interactive's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pharmagest Interactive Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:PHA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2017-12-31 146.81 23.14
2017-09-30 141.84 22.12
2017-06-30 136.88 21.11
2017-03-31 132.63 20.84
2016-12-31 128.38 20.57
2016-09-30 124.60 20.06
2016-06-30 120.82 19.54
2016-03-31 117.15 19.17
2015-12-31 113.48 18.79
2015-09-30 112.96 18.17
2015-06-30 112.44 17.55
2015-03-31 113.50 17.28
2014-12-31 114.56 17.01
2014-09-30 113.57 16.75
2014-06-30 112.58 16.50
2014-03-31 112.99 16.16
2013-12-31 113.41 15.83
2013-09-30 113.12 15.19
2013-06-30 112.83 14.56
2013-03-31 110.78 14.04
2012-12-31 108.72 13.52
2012-09-30 105.29 13.13
2012-06-30 101.87 12.74
2012-03-31 99.47 12.25
2011-12-31 97.06 11.75
2011-09-30 96.20 11.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Pharmagest Interactive has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Pharmagest Interactive used its assets more efficiently than the Europe Healthcare Services industry average last year based on Return on Assets.
  • Pharmagest Interactive's use of capital has not improved over the past 3 years (Return on Capital Employed).
X
Past performance checks
We assess Pharmagest Interactive's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pharmagest Interactive has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PHA Health

 How is Pharmagest Interactive's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pharmagest Interactive's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pharmagest Interactive is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pharmagest Interactive's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pharmagest Interactive's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pharmagest Interactive Company Filings, last reported 8 months ago.

ENXTPA:PHA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2017-12-31 115.83 16.88 55.71
2017-09-30 115.83 16.88 55.71
2017-06-30 103.35 15.71 61.48
2017-03-31 103.35 15.71 61.48
2016-12-31 103.65 10.40 55.16
2016-09-30 103.65 10.40 55.16
2016-06-30 92.77 4.96 62.25
2016-03-31 92.77 4.96 62.25
2015-12-31 91.56 1.58 55.13
2015-09-30 91.56 1.58 55.13
2015-06-30 82.13 1.49 52.67
2015-03-31 82.13 1.49 52.67
2014-12-31 81.70 1.58 47.71
2014-09-30 81.70 1.58 47.71
2014-06-30 77.00 1.46 47.15
2014-03-31 77.00 1.46 47.15
2013-12-31 76.07 2.48 45.50
2013-09-30 76.07 2.48 45.50
2013-06-30 68.62 6.51 40.40
2013-03-31 68.62 6.51 40.40
2012-12-31 66.92 3.35 41.70
2012-09-30 66.92 3.35 41.70
2012-06-30 60.30 4.13 35.88
2012-03-31 60.30 4.13 35.88
2011-12-31 58.51 4.84 31.63
2011-09-30 58.51 4.84 31.63
  • Pharmagest Interactive's level of debt (14.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (5.1% vs 14.6% today).
  • Debt is well covered by operating cash flow (162.8%, greater than 20% of total debt).
  • Pharmagest Interactive earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Pharmagest Interactive's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pharmagest Interactive has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PHA Dividends

 What is Pharmagest Interactive's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.22%
Current annual income from Pharmagest Interactive dividends. Estimated to be 1.52% next year.
If you bought €2,000 of Pharmagest Interactive shares you are expected to receive €24 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Pharmagest Interactive's pays a lower dividend yield than the bottom 25% of dividend payers in France (1.44%).
  • Pharmagest Interactive's dividend is below the markets top 25% of dividend payers in France (3.76%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:PHA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
France Market Average Dividend Yield Market Cap Weighted Average of 317 Stocks 2.8%
France Minimum Threshold Dividend Yield 10th Percentile 0.9%
France Bottom 25% Dividend Yield 25th Percentile 1.4%
France Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:PHA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 1.06 3.00
2019-12-31 0.92 3.00
2018-12-31 0.78 2.00
ENXTPA:PHA Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2018-04-03 0.750 1.280
2017-04-28 0.650 1.452
2016-05-02 0.600 1.986
2015-04-30 0.580 2.563
2014-07-03 0.500 2.407
2013-04-26 0.420 2.413
2013-03-26 0.420 2.954
2012-04-26 0.360 3.332
2012-03-26 0.360 3.892
2011-04-28 0.300 3.339
2011-01-17 0.300 3.211
2010-04-28 0.280 3.171
2010-03-29 0.280 3.249
2009-04-28 0.270 3.306
2008-09-23 0.260 3.458

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Pharmagest Interactive's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.1x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.2x coverage).
X
Income/ dividend checks
We assess Pharmagest Interactive's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pharmagest Interactive afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pharmagest Interactive has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PHA Management

 What is the CEO of Pharmagest Interactive's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dominique Pautrat, image provided by Google.
Dominique Pautrat
COMPENSATION €229,462
AGE 53
CEO Bio

Mr. Dominique Pautrat serves as the Chief Executive Officer, Managing Director and Director of Pharmagest Interactive Societe Anonyme.

CEO Compensation
  • Dominique's compensation has been consistent with company performance over the past year.
Management Team

Thierry Chapusot

TITLE
Founder & Chairman of the Board
COMPENSATION
€24K
AGE
59

Dominique Pautrat

TITLE
CEO, MD & Director
COMPENSATION
€229K
AGE
53

Thierry Ponnelle

TITLE
Director of Marketing & Commercial Strategy
COMPENSATION
€135K
AGE
58

Denis Supplisson

TITLE
Director of Solutions for Pharmacy Division - Europe
COMPENSATION
€183K
AGE
49

Jean-Yves Samson

TITLE
Chief Administration & Financial Officer

Rodolphe Zimmer

TITLE
Human Resources Director

Liza Natan

TITLE
Director of E-Laboratories Division

Thierry Poivey

TITLE
Director of Pharmacy Division - Belgium and Luxembourg

Grégory Rousseau

TITLE
Research & Development Technical Director

Yannis Nahal

TITLE
Director of E-Santé Solutions Division
Board of Directors

Dominique Pautrat

TITLE
CEO, MD & Director
COMPENSATION
€229K
AGE
53

Thierry Ponnelle

TITLE
Director of Marketing & Commercial Strategy
COMPENSATION
€135K
AGE
58

Denis Supplisson

TITLE
Director of Solutions for Pharmacy Division - Europe
COMPENSATION
€183K
AGE
49

Marie-Louise Liger

TITLE
Independent Director
COMPENSATION
€15K
AGE
66
TENURE
3.3 yrs

Thierry Chapusot

TITLE
Founder & Chairman of the Board
COMPENSATION
€24K
AGE
59
TENURE
8.7 yrs

Daniel Antoine

TITLE
Director
COMPENSATION
€5K
AGE
66

Hugues Moreaux

TITLE
Director
AGE
65

François Jacquel

TITLE
Director
COMPENSATION
€6K
AGE
60

Anne Lhote

TITLE
Director
AGE
50

Sophie Mayeux

TITLE
Independent Director
COMPENSATION
€750
AGE
61
Recent Insider Trading
  • No 3 month insider trading information.
Who owns this company?
X
Management checks
We assess Pharmagest Interactive's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap and profit (greater than 0.5% of the company's profit + 0.03% of market cap)? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pharmagest Interactive has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PHA News

External News
Loading...
Simply Wall St News

Analysts Bullish On Pharmagest Interactive SA (EPA:PHA)

Pharmagest Interactive SA (EPA:PHA) continues to post impressive revenue growth and its prospects have never been brighter. … I will conduct a high level fundamental analysis on the company by looking at its past financials and growth prospects moving forward. … Since starting in 1996 in France, the company has now grown to a market cap of €941.78m.

Simply Wall St -

Pharmagest Interactive SA (EPA:PHA): Is Healthcare Attractive?

which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impacting the sector globally … Healthcare tech is facing a structural shift in terms of technology-enabled devices, which can progress innovation clinically and cost-effectively … Growth will be driven from advancements from robotic surgery, 3D printing, implantable devices and treatment, aimed at improving outcomes and reducing costs

Simply Wall St -

Pharmagest Interactive SA (EPA:PHA): Why Return On Capital Employed Is Important

and looking to gauge the potential return on investment in Pharmagest Interactive SA (EPA:PHA). … Your return is tied to PHA’s ability to do this because the amount earned is used to invest in opportunities to grow the business or payout dividends, which are the two sources of return on investment. … Thus, to understand how your money can grow by investing in Pharmagest Interactive, you need to look at what the company returns to owners for the use of their capital, which can be done in many ways but today we will use return on capital employed (ROCE)

Simply Wall St -

Does Pharmagest Interactive SA's (EPA:PHA) 12.49% Earnings Growth Reflect The Long-Term Trend?

Assessing Pharmagest Interactive SA's (EPA:PHA) performance as a company requires looking at more than just a years' earnings data. … Below, I will run you through a simple sense check to build perspective on how Pharmagest Interactive is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its healthcare services industry peers. … PHA's trailing twelve-month earnings (from 31 December 2017) of €23.14m has

Simply Wall St -

Is Pharmagest Interactive SA (EPA:PHA) A Sell At Its Current PE Ratio?

and want to better understand how you can grow your money by investing in Pharmagest Interactive SA (EPA:PHA). … Pharmagest Interactive SA (EPA:PHA) is currently trading at a trailing P/E of 38x, which is higher than the industry average of 37.5x. … While PHA might seem like a stock to avoid or sell if you own it, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions

Simply Wall St -

Pharmagest Interactive SA (EPA:PHA): A Fundamentally Attractive Investment

Pharmagest Interactive SA (EPA:PHA) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of PHA, it

Simply Wall St -

Pharmagest Interactive SA (ENXTPA:PHA): What The Forecasts Are Telling Us

With analysts projecting … Pharmagest Interactive SA (ENXTPA:PHA) to … earnings growth of 15.41%

Simply Wall St -

Is Pharmagest Interactive SA's (EPA:PHA) Balance Sheet Strong Enough To Weather A Storm?

PHA has built up its total debt levels in the last twelve months, from €10.40M to €16.88M – this includes both the current and long-term debt. … Additionally, PHA has generated €27.48M in operating cash flow during the same period of time, resulting in an operating cash to total debt ratio of 162.80%, indicating that PHA’s debt is appropriately covered by operating cash. … Next Steps: PHA’s high cash coverage and low debt levels indicate its ability to utilise its borrowings efficiently in order to generate ample cash flow.

Simply Wall St -

Brokers' Outlook On Pharmagest Interactive SA (EPA:PHA)

ENXTPA:PHA Future Profit May 15th 18 The company is growing incredibly fast, with a year-on-year revenue growth of 14.35% over the past financial year , and a bottom line growth of 12.49%. … ENXTPA:PHA Historical Debt May 15th 18 Investors tend to get swept up by a company's growth prospects and promises, but a key element to always look at is its financial health in order to minimize the downside risk of investing. … Furthermore, PHA's debt level is at an appropriate 14.57% of equity, though it has been increasing over the past five years from 5.06%.

Simply Wall St -

PHA Company Info

Map
Description

Pharmagest Interactive SA engages in the development and commercialization of IT solutions for pharmacies and the pharmaceutical industry in Europe. The company operates through four divisions: Pharmaceuticals Solutions Europe, Solutions for Health and Medico-Social Institutions, e-Health Solutions, and Fintech. It offers LGPI, a pharmacy business management software; a range of SABCO software for the pharmacies in Belgium; OFFICINE 2016 flagship software for the pharmacies in Luxembourg; and OFFIDOSE 2.0, a pharmacy business management software. The company also provides robotic solutions for pharmacies, as well as dispenses medicines at the point of sale. In addition, it offers TITAN software suite, which provides a complete circuit of drug in the elderly housing establishment and day care centers for elderly people; and connected, secure, patient-oriented solutions for healthcare professionals. Further, the company offers patient services comprising observational tracking software; application services through mobile phone; DO-Pill, a connected pillbox, which allows patients to gain comfort and never forget their treatment; and communicating services. Additionally, it provides leasing financing solutions for the tertiary sector; and Leasa, a full Web computing gateway, which acts as a hub for accessing the financial partners, as well as managing sales financing processes. Pharmagest Interactive SA also offers IT equipment and services for pharmacy wholesalers and distributors. The company was founded in 1996 and is headquartered in Villers-les-Nancy, France. Pharmagest Interactive SA is a subsidiary of Marque Verte Sante.

Details
Name: Pharmagest Interactive SA
PHA
Exchange: ENXTPA
Founded: 1996
€919,358,334
14,948,916
Website: http://www.pharmagest.com
Address: Pharmagest Interactive SA
5 allée de Saint-Cloud,
Villers-les-Nancy,
Lorraine, 54600,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA PHA Ordinary Shares Euronext Paris FR EUR 23. Oct 2000
LSE 0R9T Ordinary Shares London Stock Exchange GB EUR 23. Oct 2000
BATS-CHIXE PHAP Ordinary Shares BATS 'Chi-X Europe' GB EUR 23. Oct 2000
ENXTPA PHA EUR0.20 Euronext Paris FR EUR 22. Sep 2018
Number of employees
Current staff
Staff numbers
929
Pharmagest Interactive employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/09/22 18:10
End of day share price update: 2018/09/21 00:00
Last estimates confirmation: 2018/09/18
Last earnings filing: 2018/04/27
Last earnings reported: 2017/12/31
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.